Literature DB >> 26182331

Having "Skin in the Game" and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs.

Hagop Kantarjian1, Michael S Mathisen2, Jeffrey H Lipton3.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26182331     DOI： 10.1001/jamaoncol.2015.1024

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  5 in total

1.  Targeted therapy: Generic imatinib - impact on frontline and salvage therapy for CML.

Authors:  Larry Gorkin; Hagop Kantarjian
Journal:  Nat Rev Clin Oncol       Date:  2016-05       Impact factor: 66.675

2.  Strategies that delay or prevent the timely availability of affordable generic drugs in the United States.

Authors:  Gregory H Jones; Michael A Carrier; Richard T Silver; Hagop Kantarjian
Journal:  Blood       Date:  2016-01-27       Impact factor: 22.113

3.  Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.

Authors:  Ya-Chen Tina Shih; Jorge E Cortes; Hagop M Kantarjian
Journal:  Lancet Haematol       Date:  2019-06-14       Impact factor: 18.959

4.  A global comparison of the cost of patented cancer drugs in relation to global differences in wealth.

Authors:  Salomon M Stemmer; Eli Rosenbaum; Daniel A Goldstein; Jonathon Clark; Yifan Tu; Jie Zhang; Fenqi Fang; Robert Goldstein
Journal:  Oncotarget       Date:  2017-05-09

5.  The cost and value of cancer drugs - are new innovations outpacing our ability to pay?

Authors:  Daniel A Goldstein; Salomon M Stemmer; Noa Gordon
Journal:  Isr J Health Policy Res       Date:  2016-09-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.